The successful capital raise and the reported cash and cash equivalents for 2023 significantly bolster Evaxion Biotech's financial position. This development is likely to be viewed positively by investors, as it provides the company with a solid financial foundation to continue its operations and research activities without the immediate need for further capital raises. The extended cash runway into April 2025 reduces short-term financial risk, potentially making EVAX more attractive to both current and prospective investors.